Cargando…

The osteoporosis care gap in Canada

BACKGROUND: The presence of a fragility fracture is a major risk factor for osteoporosis, and should be an indicator for osteoporosis diagnosis and therapy. However, the extent to which patients who fracture are assessed and treated for osteoporosis is not clear. METHODS: We performed a review of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Papaioannou, A, Giangregorio, L, Kvern, B, Boulos, P, Ioannidis, G, Adachi, JD
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420244/
https://www.ncbi.nlm.nih.gov/pubmed/15068488
http://dx.doi.org/10.1186/1471-2474-5-11
_version_ 1782121470115184640
author Papaioannou, A
Giangregorio, L
Kvern, B
Boulos, P
Ioannidis, G
Adachi, JD
author_facet Papaioannou, A
Giangregorio, L
Kvern, B
Boulos, P
Ioannidis, G
Adachi, JD
author_sort Papaioannou, A
collection PubMed
description BACKGROUND: The presence of a fragility fracture is a major risk factor for osteoporosis, and should be an indicator for osteoporosis diagnosis and therapy. However, the extent to which patients who fracture are assessed and treated for osteoporosis is not clear. METHODS: We performed a review of the literature to identify the practice patterns in the diagnosis and treatment of osteoporosis in adults over the age of 40 who experience a fragility fracture in Canada. Searches were performed in MEDLINE (1966 to January 2, 2003) and CINAHL (1982 to February 1, 2003) databases. RESULTS: There is evidence of a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada. The proportion of individuals with a fragility fracture who received an osteoporosis diagnostic test or physician diagnosis ranged from 1.7% to 50%. Therapies such as hormone replacement therapy, bisphosphonates or calcitonin were being prescribed to 5.2% to 37.5% of patients. Calcium and vitamin D supplement intake was variable, and ranged between 2.8% to 61.6% of patients. CONCLUSION: Many Canadians who experience fragility fracture are not receiving osteoporosis management for the prevention of future fractures.
format Text
id pubmed-420244
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-4202442004-06-06 The osteoporosis care gap in Canada Papaioannou, A Giangregorio, L Kvern, B Boulos, P Ioannidis, G Adachi, JD BMC Musculoskelet Disord Research Article BACKGROUND: The presence of a fragility fracture is a major risk factor for osteoporosis, and should be an indicator for osteoporosis diagnosis and therapy. However, the extent to which patients who fracture are assessed and treated for osteoporosis is not clear. METHODS: We performed a review of the literature to identify the practice patterns in the diagnosis and treatment of osteoporosis in adults over the age of 40 who experience a fragility fracture in Canada. Searches were performed in MEDLINE (1966 to January 2, 2003) and CINAHL (1982 to February 1, 2003) databases. RESULTS: There is evidence of a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada. The proportion of individuals with a fragility fracture who received an osteoporosis diagnostic test or physician diagnosis ranged from 1.7% to 50%. Therapies such as hormone replacement therapy, bisphosphonates or calcitonin were being prescribed to 5.2% to 37.5% of patients. Calcium and vitamin D supplement intake was variable, and ranged between 2.8% to 61.6% of patients. CONCLUSION: Many Canadians who experience fragility fracture are not receiving osteoporosis management for the prevention of future fractures. BioMed Central 2004-04-06 /pmc/articles/PMC420244/ /pubmed/15068488 http://dx.doi.org/10.1186/1471-2474-5-11 Text en Copyright © 2004 Papaioannou et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Papaioannou, A
Giangregorio, L
Kvern, B
Boulos, P
Ioannidis, G
Adachi, JD
The osteoporosis care gap in Canada
title The osteoporosis care gap in Canada
title_full The osteoporosis care gap in Canada
title_fullStr The osteoporosis care gap in Canada
title_full_unstemmed The osteoporosis care gap in Canada
title_short The osteoporosis care gap in Canada
title_sort osteoporosis care gap in canada
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC420244/
https://www.ncbi.nlm.nih.gov/pubmed/15068488
http://dx.doi.org/10.1186/1471-2474-5-11
work_keys_str_mv AT papaioannoua theosteoporosiscaregapincanada
AT giangregoriol theosteoporosiscaregapincanada
AT kvernb theosteoporosiscaregapincanada
AT boulosp theosteoporosiscaregapincanada
AT ioannidisg theosteoporosiscaregapincanada
AT adachijd theosteoporosiscaregapincanada
AT papaioannoua osteoporosiscaregapincanada
AT giangregoriol osteoporosiscaregapincanada
AT kvernb osteoporosiscaregapincanada
AT boulosp osteoporosiscaregapincanada
AT ioannidisg osteoporosiscaregapincanada
AT adachijd osteoporosiscaregapincanada